
Search
Selected Filters
Filter Results
Displaying 21–30 of 254 research results
-
Dec 2, 2022
SparingVision Receives Authorization to Launch US Clinical Trial for its Cone-Preserving Treatment
The emerging therapy is designed to work independent of the mutated gene causing retinitis pigmentosa
-
Dec 2, 2022
Opus Genetics to Launch Gene Therapy Clinical Trial for LCA5 Patients
The LCA5 gene therapy will be the first emerging Opus treatment to move into a human study
-
Nov 18, 2022
Editas Reports Results for 14 Participants in its Phase 1/2 CRISPR/Cas9 Clinical Trial for LCA10
The company is seeking a partner to move the LCA10 program forward
-
Oct 10, 2022
Recap of Retinal Disease News from the 2022 Meeting of the American Academy of Ophthalmology
Reports on emerging therapies for dry age-related macular degeneration (geographic atrophy), Stargardt disease, and X-linked retinitis pigmentosa are included
-
Oct 3, 2022
Atsena’s LCA-GUCY2D Gene Therapy Improves Vision in Phase 1/2 Clinical Trial
The company is planning to move the emerging treatment into a pivotal trial
-
Oct 3, 2022
Small data sets present challenges for developing rare disease AI tools
-
Sep 8, 2022
Iveric Bio’s Zimura for Advanced Dry AMD Meets Endpoint in Second Phase 3 Clinical Trial
The company plans to seek FDA approval for the emerging therapy in first quarter of 2023
-
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
-
Aug 11, 2022
ProQR Seeking to Partner Ophthalmic Programs
The company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner
-
Aug 10, 2022
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners